Is Curanex Pharmaceuticals Inc Common Stock (CURX) overvalued? · $8.9M cap
Curanex Pharmaceuticals Inc Common Stock (CURX) is a biotechnology company listed on NASDAQ.
This page asks whether Curanex Pharmaceuticals Inc Common Stock (CURX) looks expensive on cached numbers — not a short thesis.
No cached income statement for CURX, so there is no earnings base to call rich or cheap.
CURX currently screens at market cap $8.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CURX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CURX stock page for the full model, not this heading.
Not investment advice.